Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Cordova, Adriana ^a   Toia, Francesca ^a   la Mendola, Carmela ^a   Orlando, Valentina ^a   Meraviglia, Serena ^a   Rinaldi, Gaetana ^a   Todaro, Matilde ^a   Cicero, Giuseppe ^a   Zichichi, Leonardo ^a,b   Donni, Paolo Li ^c   Caccamo, Nadia ^a   Stassi, Giorgio ^a   Dieli, Francesco ^a   Moschella, Francesco ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Azienda Ospedaliera S Antonio di Abate di Trapani   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CELL ISOLATION; CELL KILLING; CYTOKINE PRODUCTION; CYTOTOXICITY; EFFECTOR CELL; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; IN VITRO STUDY; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MEMORY CELL; PHENOTYPE; PRIMARY TUMOR; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84870001727     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049878     Document Type: Article

References (53)

1. Speeckaert R, van Geel N, Vermaelen KV, Lambert J, Van Gele M, et al. (2011) Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell Melanoma Res 24: 334-344.
2. Kalialis LV, Drzewiecki KT, Klyver H, (2009) Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 19: 275-282.
3. Ceballos PI, Barnhill RL, (1993) Spontaneous regression of cutaneous tumors. Adv Dermatol 8: 229-261.
4. Clemente CG, Mihm MC Jr, Bufalino R, ZurridaS, Collini P, et al. (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77: 1303-1310.
5. Rao UN, Lee SJ, Luo W, Mihm MC Jr, Kirkwood JM, (2010) Presence of tumor infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol 133: 646-653.
6. Atkins MB, Kunkel L, Sznol M, Rosenberg SA, (2000) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6: S11-S14.
7. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, et al. (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24: 4738-4745.
8. Sasada T, Suekane S, (2011) Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. Immunotherapy 3: 1235-1251.
9. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW, (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105: 93-103.
10. Cipponi A, Wieers G, van Baren N, Coulie PG, (2011) Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother 60: 1153-1160.
11. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
12. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357.
13. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, et al. (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239.
14. Weber J, (2008) Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 13: 16-25.
15. Ribas A, (2008) Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist 13: 10-5.
16. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
17. Blank C, Gajewski TF, Mackensen A, (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54: 307-314.
18. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, et al. (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14: 3044-3051.
19. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, et al. (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175.
20. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, et al. (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188: 1641-1650.
21. Nishimura MI, Avichezer D, Custer MC, Lee CS, Chen C, et al. (1999) MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. Cancer Res 59: 6230-6238.
22. Hayday AC, (2009) γδ T cells and the lymphoid stress-surveillance response. Immunity 31: 184-196.
23. Groh V, Porcelli S, Fabbi M, Lanier LL, Picker LJ, et al. (1989) Human lymphocytes bearing T cell receptor γ/δ are phenotypically diverse and evenly distributed throughout the lymphoid system. J Exp Med 169: 1277-1294.
24. Bonneville M, O'Brien RL, Born WK, (2010) γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 10: 467-478.
25. Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, et al. (1994) Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands. Science 264: 267-270.
26. Eberl M, Hintz M, Reichenberg A, Kollas AK, Wiesner J, et al. (2003) Microbial isoprenoid biosynthesis and human γδ T cell activation. FEBS Lett 544: 4-10.
27. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR, (1995) Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature 375: 155-158.
28. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, et al. (2003) Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197: 163-168.
29. Kistowska M, Rossy E, Sansano S, Gober HJ, Landmann R, et al. (2008) Dysregulation of the host mevalonate pathway during early bacterial infection activates human γδ TCR cells. Eur J Immunol 38: 2200-220.
30. Sireci G, Espinosa E, Di Sano C, Salerno A, Fournié JJ, et al. (2001) Differential activation of human γδ T cells by nonpeptide phosphoantigens. Eur J Immunol 31: 1628-1634.
31. Guo RT, Cao R, Liang PH, Ko TP, Chang TH, et al. (2007) Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci USA 104: 10022-10027.
32. Vermijlen D, Ellis P, Langford C, Klein A, Engel R, et al. (2007) Distinct cytokine-driven responses of activated blood γδ T cells: insights into unconventional T cell pleiotropy. J Immunol 178: 4304-4314.
33. Wesch D, Glatzel A, Kabelitz D, (2001) Differentiation of resting human peripheral blood γδ T cells toward Th1- or Th2-phenotype. Cell Immunol 212: 110-117.
34. Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, et al. (2011) Differentiation, phenotype and function of interleukin-17-producing human Vγ9Vδ2 T cells. Blood 118: 129-138.
35. Meraviglia S, Caccamo N, Salerno A, Sireci G, Dieli F, (2010) Partial and ineffective activation of Vγ9Vδ2 T cells by Mycobacterium tuberculosis-infected dendritic cells. J Immunol 185: 1770-1776.
36. Eberl M, Roberts GW, Meuter S, Williams JD, Topley N, et al. (2009) A rapid crosstalk of human γδ T cells and monocytes drives the acute inflammation in bacterial infections. PLoS Pathog 5: e1000308.
37. Caccamo N, Battistini L, Bonneville M, Poccia F, Fournié JJ, et al. (2006) CXCR5 identifies a subset of Vγ9Vδ2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production. J Immunol 177: 5290-5295.
38. Bansal RR, Mackay CR, Moser B, Eberl M, (2012) IL-21 enhances the potential of human γδ T cells to provide B-cell help. Eur J Immunol 42: 110-119.
39. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206.
40. Motulsky H (1995) Choosing an appropriate sample size. Intuitive Biostatistics 199-200. Oxford Univ. Press, New York.
41. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, et al. (2003) Differentiation of effector/memory Vδ2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 198: 391-397.
42. Ebert LM, Meuter S, Moser B, (2006) Homing and function of human skin γδ T cells and NK cells: relevance for tumor surveillance. J Immunol 176: 4331-4336.
43. Laggner U, Di Meglio P, Perera GK, Hundhausen C, Lacy KE, et al. (2011) Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol 187: 2783-2793.
44. Li J, MJ Herold, B Kimmel, I Müller, B Rincon-Orozco, et al. (2009) Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vγ9Vδ2 T cells. J Immunol 182: 8118-8124.
45. Benzaïd I, Mönkkönen H, Stresing V, Bonnelye E, Green J,et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vγ9Vδ2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 71: 4562-4572.
46. Scotet E, LO Martinez, E Grant, R Barbaras, P Jenö, et al. (2005) Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22: 71-80.
47. Inman BA, X Frigola, KJ Harris, SM Kuntz, CM Lohse, et al. (2008) Questionable relevance of γδ T lymphocytes in renal cell carcinoma. J Immunol 180: 3578-3584.
48. Ma C, Q Zhang, J Ye, F Wang, Y Zhang, et al. (2012) Tumor-Infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J Immunol 189 (published online 3 October 2012).
49. Rosenberg SA, Yang JC, Restifo NP, (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
50. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, et al. (2007) Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67: 7450-7457.
51. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, et al. (2010) In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 161: 290-297.
52. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, et al. (2008) Phase-I study of Innacell γδ, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57: 1599-1609.
53. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, et al. (2007) Safety profile and anti-tumor effects of adoptive immunotherapy using γδ T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56: 469-476.